Cost-effectiveness of inclisiran in patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective

Mochou Liu, Xinyue Zhang, Mengwen Feng, Qingfeng He, Zhen Feng · 2026

Read Cost-effectiveness of inclisiran in patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective by Mochou Liu, Xinyue Zhang, Mengwen Feng, Qingfeng He, Zhen Feng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350294.txt.

Description

Mochou Liu and co-authors weighed whether inclisiran, a twice-yearly injection that durably lowers harmful cholesterol, is good value for Chinese patients who already have cardiovascular disease. Many such patients miss cholesterol targets on statins alone. Their 2026 model simulated a lifetime of treatment from the health system's viewpoint, comparing the injection plus statins against statins alone and testing the result against China's accepted cost threshold.

Adding inclisiran bought extra healthy life years at a cost per year below the national threshold. The answer depended most on how much the drug cuts deaths, on discounting choices, and on its price, yet it stayed cost-effective in every scenario tried. A probability analysis put the chance of good value above ninety-five percent. The authors back wider use within the Chinese system.

Catalog record

CREATORMochou Liu, Xinyue Zhang, Mengwen Feng, Qingfeng He, Zhen Feng
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31850
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0350294

Browse the full library · About the Tower of Babel